Notice to All Deutsche Bank Securities Inc. Clients From the Securities Arbitration Law Firm of Klayman & Toskes, P.A. NEW YORK, March 17 /PRNewswire/ -- The Law Firm of Klayman & Toskes, P.A. ("K&T") (http://www.nasd-law.com/ ) continues to pursue individual securities arbitration claims before the National Association of Securities Dealers ("NASD") and the New York Stock Exchange ("NYSE") on behalf of high net worth investors who prefer not to participate in, and investors who are ineligible to recover from the $433 million research analyst distribution fund created by the Securities and Exchange Commission ("SEC"). The distribution fund follows the decision against several brokerage firms including Deutsche Bank Securities Inc. (NYSE:DB) by the SEC (SEC v. Deutsche Bank Securities Inc, No. 04 Civ. 06909 WHP) for violation of the Securities and Exchange Act of 1934 ("Exchange Act") and for violation of NASD rules 2110, and 2210 and NYSE rules 401, 472 and 476 (a)(6). Although the market capitalization lost in excess of $4 billion, the distribution fund has only allocated $28.75 million for the following stocks purchased through Deutsche Bank Securities Inc. 1. Getty Images, Inc. (NYSE:GYI) Apr. 5, 02 - Jul. 4, 02 2. Oracle Corporation (NASDAQ:ORCL) May. 31, 01 - Aug. 29, 01 3. Transkaryotic Therapies Inc. (NASDAQ:TKTX) Jul. 13, 01 - Oct. 11, 01 4. Trimeris, Inc (NASDAQ:TRMS) Dec. 28, 01 - Mar. 28, 02 5. Untied Therapeutics Corp. (NASDAQ:UTHR) Mar. 7, 00 - Jun. 5, 00 K&T currently represents numerous high net worth investors who have filed individual securities arbitration claims. Investors suffering large losses achieve an overall higher recovery rate through arbitration than any other means. Empirical evidence shows that when an investor suffers losses in larger amounts, usually in excess of $100,000, an individual dispute resolution process such as an arbitration claim filed before the NYSE or the NASD may be the best means of recovering losses suffered. K&T has offices in California, Florida, Nebraska, and New York and represents investors throughout the nation. The sole purpose of this release is to investigate, on behalf of our clients, sales practice violations of licensed brokers at major investment firms. If you wish to discuss this announcement or have information relevant to our securities arbitration claims, please contact Lawrence L. Klayman at 1-888-997-9956 or visit us on the web at http://www.nasd-law.com/ . DATASOURCE: Klayman & Toskes, P.A. CONTACT: Lawrence L. Klayman of Klayman & Toskes, P.A., +1-888-997-9956 Web site: http://www.nasd-law.com/

Copyright

Transkaryotic Therapies (NASDAQ:TKTX)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Transkaryotic Therapies Charts.
Transkaryotic Therapies (NASDAQ:TKTX)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Transkaryotic Therapies Charts.